B. Riley Issues Negative Forecast for Novavax Earnings

Novavax, Inc. (NASDAQ:NVAX) – Equities research analysts at B. Riley cut their Q1 2025 EPS estimates for shares of Novavax in a note issued to investors on Monday, March 3rd. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn ($0.46) per share for the quarter, down from their previous estimate of ($0.38). The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. B. Riley also issued estimates for Novavax’s Q2 2025 earnings at $0.64 EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at $0.11 EPS, FY2027 earnings at $0.61 EPS, FY2028 earnings at $0.59 EPS and FY2029 earnings at $1.36 EPS.

Other analysts have also recently issued reports about the company. BTIG Research assumed coverage on Novavax in a report on Friday, February 28th. They set a “buy” rating and a $19.00 price objective on the stock. TD Cowen upgraded shares of Novavax to a “hold” rating in a research report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $18.00.

Novavax Trading Up 2.7 %

Shares of NVAX stock opened at $7.89 on Wednesday. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -3.49, a price-to-earnings-growth ratio of 2.85 and a beta of 2.14. Novavax has a 12-month low of $3.81 and a 12-month high of $23.86. The stock’s 50-day moving average price is $8.47 and its 200-day moving average price is $9.86.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to analysts’ expectations of $85.48 million. During the same period in the prior year, the firm earned ($1.44) EPS.

Hedge Funds Weigh In On Novavax

A number of large investors have recently bought and sold shares of the business. E Fund Management Co. Ltd. lifted its position in Novavax by 5.1% during the fourth quarter. E Fund Management Co. Ltd. now owns 25,340 shares of the biopharmaceutical company’s stock valued at $204,000 after acquiring an additional 1,219 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,598 shares during the period. Bank of New York Mellon Corp boosted its position in Novavax by 0.4% in the 4th quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company’s stock worth $3,509,000 after purchasing an additional 1,664 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Novavax by 12.0% in the third quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 2,072 shares during the period. Finally, Federated Hermes Inc. grew its holdings in Novavax by 4.4% in the fourth quarter. Federated Hermes Inc. now owns 50,506 shares of the biopharmaceutical company’s stock valued at $406,000 after purchasing an additional 2,124 shares during the period. Institutional investors own 53.04% of the company’s stock.

Insider Buying and Selling at Novavax

In other news, Director James F. Young sold 4,600 shares of the company’s stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $8.48, for a total transaction of $39,008.00. Following the transaction, the director now owns 57,160 shares of the company’s stock, valued at approximately $484,716.80. This represents a 7.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Rachel K. King sold 4,150 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the sale, the director now owns 14,770 shares in the company, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,150 shares of company stock worth $119,641 over the last quarter. Insiders own 1.00% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.